Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535931) titled 'A Phase I/? Clinical Trial for HS_SW01 Cells Injection in the Treatment of Systemic Sclerosis' on April 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Shenzhen Huishan Biotechnology Co., Ltd.

Condition: Systemic Sclerosis (SSc)

Intervention: Drug: HS_SW01 cells injection Drug: HS_SW01 cells injection

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: April 10, 2026

Target Sample Size: 21

To know more, vis...